COVID-19 and Cognitive Decline in Older Adults with High-Cardiovascular Risk: A Post Hoc Analysis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shyam Sangeetha, Gómez-Martínez Carlos, Ni Jiaqi, Gaforio José J, Martínez-González Miguel Ángel, Corella Dolores, Martínez J Alfredo, Alonso-Gómez Ángel M, Wärnberg Julia, Vioque Jesús, Romaguera Dora, López-Miranda José, Estruch Ramon, Tinahones Francisco J, Lapetra José, Serra-Majem Lluís, Bueno-Cavanillas Aurora, Tur Josep A, Martín-Sánchez Vicente, Pintó Xavier, Delgado-Rodríguez Miguel, Matía-Martín Pilar, Vidal Josep, Vázquez Clotilde, Daimiel Lidia, Ros Emilio, Fernandez-Aranda Fernando, Hernández-Cacho Adrián, Buil-Cosiales Pilar, Sorli Jose V, Castañer Olga, Garcia-Rios Antonio, Oncina-Canovas Alejandro, Pérez-Farinós Napoleón, Nafria Mar, Casas Rosa, Martínez-Diz Silvia, Tojal-Sierra Lucas, Am Gómez-Pérez, Toledo Estefania, Fernández-Carrión Rebeca, Bayón Álvaro Morán, Torres-Peña Jose David, Compañ-Gabucio Laura, Vázquez-Ruiz Zenaida, Babio Nancy, Fitó Montserrat, Salas-Salvadó Jordi
Аннотация
Cognitive decline has been reported as a short-term sequela in patients hospitalized for coronavirus disease-19 (COVID-19). Whether COVID-19 is associated with late cognitive impairment in older free-living individuals with high cardiovascular risk, a group at greater risk of cognitive decline, is unknown. We determined this association of COVID-19 through a longitudinal evaluation of post-COVID-19 cognitive performance and impairment as post hoc analysis in 5,179 older adults (48% female) with mean (SD) age 68.5 (5.0) years, body mass index 31.7 (3.7) kg/m2, harboring ≥ 3 criteria for metabolic syndrome (e.g., hypertension, hyperlipidemia, hyperglycemia etc.) enrolled in PREDIMED-Plus trial. Pre- and post-COVID-19 cognitive performance was ascertained from scheduled assessments conducted using a battery of neuropsychological tests, including 5 domains: Global Cognitive Function, General Cognitive Function, Execution Function, Verbal Fluency and Attention domains, which were standardized for the cohort. Cognitive impairment was defined as the bottom 10 percentile of the sample. Multivariable linear and logistic regression models assessed the association of COVID-19 with cognitive decline and impairment, respectively. After a mean 50-week follow-up, no significant associations were observed between COVID-19 status and post-COVID-19 scores of all tapped neuropsychological domains, except Global Cognitive Function (GCF). When fully adjusted, COVID-19 was marginally associated with higher (better) post-pandemic GCF score (βadj (95% CI): 0.06 (0.00, 0.13) p=.05). However, the odds for post-COVID-19 cognitive impairment in GCF domain were not associated with the disease (ORadj (95% CI): 0.90 (0.53, 1.51) p=.68). In the PREDIMED-Plus cohort, COVID-19 status and cognitive impairment determined 50 weeks post-infection showed no association in older adults at high cardiovascular risk. This suggests that cognitive changes observed shortly after COVID-19 revert over time. However, cautious interpretation is warranted as these data were obtained within the framework of a clinical trial encouraging a healthy lifestyle.